HCQS 400 Mg (Hydroxychloroquine)

HCQS 400mg (Hydroxychloroquine Sulfate): Complete Medical Guide — Uses, Dosage, Side Effects & Precautions 

 Medically reviewed by Dr. Emily Brown, PharmD, PhD — Pharmaceutical Scientist & Drug Information Specialist. Content verified against current FDA-approved product monographs, American Academy of Ophthalmology screening guidelines, and peer-reviewed pharmacological literature. 

Regulatory Note: HCQS 400mg contains Hydroxychloroquine Sulfate, manufactured by IPCA Laboratories, India, typically supplied as two 200mg tablets or a 400mg-equivalent dose. The originator branded product, Plaquenil, received initial FDA approval in 1955. HCQS 400mg is a prescription-only medication in all regulated markets, and is FDA-referenced for rheumatoid arthritis, systemic lupus erythematosus, chronic discoid lupus erythematosus, and malaria. 

HCQS 400mg refers to a 400mg daily dose of Hydroxychloroquine Sulfate, manufactured by IPCA Laboratories, India, and typically dispensed as tablets that together provide this daily amount (each 200mg tablet is equivalent to 155mg of hydroxychloroquine base). It belongs to the class of antimalarial and disease-modifying antirheumatic drugs (DMARDs), working by suppressing overactivity of the immune system that drives inflammation, swelling, and pain in autoimmune conditions such as rheumatoid arthritis and lupus. 

A critical correction to a dangerous claim in a competitor document: One reviewed source describing HCQS 400mg incorrectly states that “adults and children of all ages can take this medicine” and that it is “generally safe for breastfeeding and pregnant women.” Both claims are inaccurate and potentially unsafe. The FDA prescribing label explicitly states hydroxychloroquine sulfate tablets are not recommended in paediatric patients weighing less than 31 kg, because the lowest available tablet strength (200mg) exceeds the appropriate dose for these patients and the tablet cannot be safely divided. Regarding pregnancy, the FDA label does not describe the drug as “generally safe” — rather, it frames the decision as a risk-benefit balance between the risks of untreated maternal disease (malaria, lupus, or rheumatoid arthritis) and any potential medication risk, to be assessed individually with a physician. Neither blanket claim should guide a patient’s decision-making. 

Two serious risks requiring long-term monitoring — retinal toxicity and cardiac effects — are addressed in dedicated detail below, reflecting current 2025–2026 clinical guidance that goes beyond what either competitor document covers. 

 What is HCQS 400mg? 

HCQS 400mg is a dosing regimen of Hydroxychloroquine Sulfate, manufactured by IPCA Laboratories Ltd., India — typically achieved through two 200mg tablets taken together, or through single higher-strength formulations where locally available. The equivalent branded product in the United States is Plaquenil 

At the 400mg total daily dose, HCQS is positioned as either the upper end of chronic maintenance dosing for rheumatoid arthritis and lupus, or a component of the initial higher-dose regimen (400–600mg/day) used at the start of rheumatoid arthritis treatment before stepping down. Because dosing at this level approaches or reaches the retinopathy-relevant threshold for many patients based on body weight, understanding weight-based dosing (discussed below) is particularly important at the 400mg level. 

How Does HCQS 400mg Work? 

Mechanism of Action 

Hydroxychloroquine exerts two distinct pharmacological actions depending on the condition being treated: 

• Antimalarial action: Hydroxychloroquine concentrates within the acidic digestive (food) vacuole of the malaria parasite, raising the internal pH and interfering with the parasite’s ability to detoxify haem released during haemoglobin digestion — disrupting the parasite’s metabolism and causing its death. 

• Immunomodulatory / DMARD action: As a Disease-Modifying Anti-Rheumatic Drug, hydroxychloroquine suppresses overactivity of the immune system responsible for the inflammation, joint swelling, and pain seen in rheumatoid arthritis and lupus. Proposed mechanisms include interference with Toll-like receptor (TLR7 and TLR9) signalling, reduced antigen presentation, and decreased production of pro-inflammatory cytokines including IL-6, IFN-α, and TNF-α. Importantly, this action addresses the underlying disease process, not just symptoms — which is why it is classified as a DMARD rather than a simple anti-inflammatory or analgesic. 

At the cellular level, hydroxychloroquine has also been shown to inhibit the P-glycoprotein (P-gp) drug efflux transporter at higher concentrations, and to induce genes regulated by the pregnane X receptor (PXR) and aryl hydrocarbon receptor (AhR) pathways — findings from pharmacokinetic transporter research (Weiss et al., 2020) that help explain several of its documented drug interactions (see below). 

Pharmacokinetics 

Following a single 200mg oral dose of hydroxychloroquine sulfate, the mean fraction of the dose absorbed is approximately 0.74 (74%) compared to intravenous administration, with a plasma time-to-peak concentration (Tmax) of approximately 3.3 to 3.7 hours, per the FDA prescribing label. The drug then undergoes extensive redistribution into tissues, particularly melanin-rich tissues such as the retina, contributing to an extremely long elimination half-life of approximately 40–50 days. This prolonged tissue retention is central to understanding both its therapeutic durability and its retinal toxicity risk profile. 

Uses and FDA-Referenced Indications of HCQS 400mg 

1. Rheumatoid Arthritis 

At the 400mg level, HCQS is used both as part of the initial dosing phase (400–600mg/day) for acute and chronic rheumatoid arthritis, and — once a good clinical response is obtained — the dose is typically reduced by 50% to a maintenance level, which may still be as high as 400mg/day in some patients depending on weight and response. Its action is cumulative, and maximal effect may take weeks to months. 

2. Systemic Lupus Erythematosus (SLE) 

HCQS 400mg represents the upper end of the standard dosing range (200–400mg daily) for SLE, used to control disease activity and reduce the frequency of flares affecting joints, skin, and other organ systems. 

3. Chronic Discoid Lupus Erythematosus 

Similarly dosed at 200–400mg daily for the skin-limited form of lupus, which causes disc-shaped lesions typically in sun-exposed areas. 

4. Malaria — Treatment and Prophylaxis 

For acute uncomplicated malaria treatment, an 800mg initial dose is followed by 400mg doses at 6, 24, and 48 hours. For prophylaxis, 400mg is taken weekly, starting 2 weeks before travel to an endemic region and continuing for 4 weeks after return. As with all hydroxychloroquine use for malaria, it is only effective in regions without documented chloroquine resistance and does not treat complicated (severe) malaria. 

Important clarification (correcting allday.docx): One competitor document states, “If you take this drug to treat arthritis, you do not need an extra dosage to prevent malaria.” This is technically accurate in spirit but potentially confusing as worded — the point is that HCQS taken for rheumatoid arthritis or lupus provides no reliable additional protection against malaria beyond what its dose happens to provide, and travellers requiring malaria prophylaxis should discuss this specifically with a travel medicine specialist rather than assume their arthritis regimen is sufficient or appropriately timed for malaria prevention. 

 Dosage and Administration of HCQS 400mg 

 

Indication	FDA / Clinical Dosing Regimen
Rheumatoid arthritis — initial dose	400–600 mg daily, single or two divided doses
Rheumatoid arthritis — maintenance	Reduce by 50% once response achieved; 200–400 mg daily
Systemic Lupus Erythematosus (SLE)	200, 300, or 400 mg daily, single or divided doses
Chronic Discoid Lupus Erythematosus	200, 300, or 400 mg daily
Malaria treatment (uncomplicated)	800 mg initial dose, then 400 mg at 6h, 24h, and 48h
Malaria prophylaxis	400 mg weekly, from 2 weeks before travel to 4 weeks after return
Retinopathy-safe ceiling (chronic use)	≤ 5 mg/kg of real (actual) body weight per day — AAO guideline
Paediatric use	Not recommended if body weight <31 kg — 200mg tablet cannot be safely divided

 How to Take HCQS 400mg 

• Administer orally with food or milk — an FDA label instruction that reduces gastrointestinal side effects 
• Swallow tablets whole. Do not crush, chew, or divide — the FDA label explicitly states tablets should not be divided 
• Take at the same time each day for consistent drug levels and better adherence 
• Complete the full prescribed duration — benefits for RA and lupus may take weeks to months to become apparent 
• Do not adjust your dose without consulting your healthcare provider, particularly given the weight-based retinopathy risk threshold discussed below 

Missed Dose 

Take the missed dose as soon as possible. If it is nearly time for the next scheduled dose, skip the missed dose and continue as normal. Do not double the next dose to compensate. 

Overdose 

Hydroxychloroquine overdose can be serious, particularly due to cardiac effects. Reportable symptoms include dizziness, confusion, increased heartbeat, tremor, and sweating. More severe overdose can progress to convulsions and cardiac arrest. Seek emergency medical attention or contact your doctor immediately if overdose is suspected — this is a medical emergency, not a wait-and-see situation. 

 Side Effects of HCQS 400mg 

Common Side Effects 

• Nausea and vomiting 
• Diarrhoea 
• Headache 
• Loss of appetite 
• Upset stomach / abdominal pain 
• Skin rash or itching 
• Bleaching or lightening of hair 
• Dizziness 
• Mood changes 
• Nervousness 

Less Common but Clinically Important Side Effects 

• Blurred vision — may be an early sign of retinal effects; report promptly (see Retinal Toxicity section) 
• Muscle weakness — may indicate hydroxychloroquine-induced myopathy with prolonged use 
• Ringing or buzzing in the ears (tinnitus) 
• Sore throat — rarely may indicate a blood dyscrasia; report if accompanied by fever or unusual fatigue 

 Retinal Toxicity — Why Weight-Based Dosing Matters at 400mg 

At the 400mg daily dose level, retinal toxicity risk deserves particular attention, since 400mg/day exceeds the recommended retinopathy-safe ceiling of 5mg/kg of real body weight for patients weighing less than 80kg — a calculation neither competitor document walks the reader through. 

The FDA prescribing label states plainly: “Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate.” Documented risk factors include: 

• Daily doses exceeding 6.5 mg/kg (5 mg/kg base) of actual body weight 
• Duration of use greater than 5 years 
• Subnormal kidney function (glomerular filtration rate) 
• Concomitant use of tamoxifen 
• Pre-existing macular disease 

In November 2025, the American Academy of Ophthalmology (AAO) published its first major revision to hydroxychloroquine retinopathy screening guidance in nearly a decade, in the journal Ophthalmology. Key points include: 

• Unpredictable onset: The retina can remain clinically normal for years before toxicity develops — meaning years of prior tolerance do not guarantee continued safety. 
• Ethnicity-dependent pattern: European-heritage patients typically show a parafoveal toxicity pattern; East Asian-heritage patients more often show a pericentral pattern — both must be screened for using appropriate protocols. 
• Screening schedule: Baseline examination at or near treatment start, then annual screening after 5 years of continuous use for low-risk patients (sooner for high-risk patients, including anyone exceeding the 5mg/kg threshold). 
• Progression after stopping: A study published in Retina (2019) found that toxicity can continue to progress for up to 20 years after the drug is discontinued, which is why proactive screening — not waiting for symptoms — is essential. 

A 2024 study in JAMA Network Open (Jorge et al.) specifically examined risk factors for hydroxychloroquine retinopathy and its subtypes, reinforcing that dose calibrated to actual body weight, not a flat mg dose, is the appropriate way to minimise risk — an important nuance at the 400mg dose level, where a lighter-weight patient may unknowingly be above the recommended per-kilogram ceiling. 

Warning signs requiring immediate discontinuation and ophthalmological evaluation: Any abnormality in visual acuity, visual fields, or the retinal macular area (pigmentary changes, loss of foveal reflex), or unexplained visual symptoms such as light flashes and streaks. Paracentral scotoma to red targets (“premaculopathy”) signals early retinal dysfunction and warrants prompt evaluation. 

 Cardiac Effects — Cardiomyopathy and QT Prolongation 

The FDA prescribing label contains an explicit warning that neither competitor document adequately conveys: “Post-marketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate as well as with use of chloroquine. Hydroxychloroquine sulfate prolongs the QT interval. Ventricular arrhythmias and torsades de pointes have been reported.” 

This cardiac risk is compounded by several of the drug interactions detailed below (notably other QT-prolonging medications), and is a key reason overdose is treated as a medical emergency. Patients experiencing palpitations, unexplained shortness of breath, fainting, or irregular heartbeat should contact their healthcare provider promptly. Those with pre-existing heart disease, arrhythmia history, or electrolyte imbalances warrant closer cardiac monitoring while on HCQS 400mg. 

 Drug Interactions 

HCQS 400mg has an extensive, well-documented list of drug interactions — considerably more nuanced than either competitor document conveys. The following table incorporates quantified findings from clinical pharmacology references and the FDA prescribing label: 

 

Drug / Substance	Clinical Action	Mechanism / Risk
Mefloquine	Avoid combination	Both lower seizure threshold — combined use “drastically increases” seizure risk, especially with epilepsy history
Cimetidine	Avoid or use with caution	May double hydroxychloroquine blood levels (based on documented 2-fold chloroquine interaction)
Cyclosporine	Monitor cyclosporine levels closely	HCQ increases cyclosporine concentration — risk of nausea, kidney damage, hypertension, jaundice
Digoxin	Monitor digoxin levels closely	HCQ may increase serum digoxin concentration — toxicity risk
Methotrexate	Use together should be avoided	May increase methotrexate blood levels — risk of toxicity (nausea, GI ulcers, renal failure)
Praziquantel	Interaction cannot be ruled out	Structurally similar chloroquine reduces praziquantel bioavailability
Antiarrhythmics / QT-prolonging drugs (amiodarone, moxifloxacin)	Avoid combination	Increased risk of inducing ventricular arrhythmias
Antiepileptic drugs (carbamazepine, phenytoin, phenobarbital)	Monitor seizure control	HCQ may lower seizure threshold, reducing anticonvulsant efficacy
Antidiabetic drugs (insulin, glipizide, glyburide)	Monitor blood glucose closely	HCQ can potentiate glucose-lowering effect — hypoglycaemia risk
Neostigmine / Pyridostigmine (myasthenia gravis drugs)	Use with caution	HCQ may antagonise their effect, worsening myasthenic symptoms
Kaolin and antacids (aluminium/magnesium)	Separate dosing by several hours	Reduces hydroxychloroquine absorption

Receptor Antagonists — A Notable Omission in Competitor Content 

cheap.docx lists several H2-receptor antagonists (famotidine, roxatidine, lafutidine, nizatidine, ranitidine) as interacting medications without explaining the mechanism. The clearest documented evidence concerns cimetidine specifically: concomitant use has been shown to produce a twofold increase in chloroquine exposure, and — because hydroxychloroquine shares close structural and pharmacokinetic similarity with chloroquine — a similar interaction with hydroxychloroquine cannot be ruled out, according to the MedCentral clinical pharmacology monograph (2024). Concomitant use of cimetidine with HCQS 400mg should generally be avoided or approached with caution and dose adjustment. 

Real-World Interaction Prevalence Data 

A 2024 observational study (the GeroCovid study, published in Reports, 2024) examined drug interactions in 487 hospitalised patients aged 60 and above who were treated with hydroxychloroquine or chloroquine. It found that 52.4% of patients had at least one documented drug interaction, and 23.4% had more than two interactions — with the most common interacting medications being lopinavir/ritonavir, azithromycin, tocilizumab, levofloxacin, clarithromycin, amlodipine, and trazodone. This underscores why a full medication review is essential before and during HCQS 400mg therapy, particularly in older patients on multiple medications. 

Precautions and Warnings 

Psoriasis 

Use of hydroxychloroquine in patients with psoriasis may precipitate a severe attack of the condition — correctly noted by allday.docx, but worth reinforcing: this medication should generally be avoided in psoriasis patients unless a physician determines the benefit outweighs this specific risk. 

Porphyria 

HCQS 400mg is contraindicated in patients with porphyria, as 4-aminoquinoline compounds can exacerbate this metabolic disorder. 

G6PD Deficiency 

Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which increases susceptibility to haemolytic anaemia with certain antimalarial drugs. 

Blood Disorders and Monitoring 

Long-term monitoring of white blood cell count, haemoglobin, and platelet count is recommended, as hydroxychloroquine can rarely cause blood dyscrasias including aplastic anaemia, agranulocytosis, leukopenia, and thrombocytopenia. 

Hypoglycaemia 

HCQS 400mg can lower blood glucose levels, an effect noted correctly in cheap.docx. Patients — particularly those with diabetes or on antidiabetic medications — should be aware of hypoglycaemia symptoms including cold sweats, cool pale skin, tremor, and anxious feelings, and should have regular blood glucose monitoring while on this medication. 

Neuromuscular and Musculoskeletal Effects 

Long-term use has been associated with skeletal muscle myopathy — presenting as progressive muscle weakness — and rarely, effects resembling myasthenia gravis. Periodic assessment of muscle strength is warranted with prolonged use, and its interaction with myasthenia gravis medications (neostigmine, pyridostigmine) is noted in the interaction table above. 

Liver and Kidney Disease 

Use with caution in hepatic or renal impairment, as this may affect drug clearance and increase toxicity risk, including retinal and cardiac effects. 

Pregnancy and Breastfeeding 

As addressed above, the FDA label frames hydroxychloroquine use in pregnancy as a risk-benefit assessment, not a blanket safety statement. Untreated rheumatoid arthritis, lupus, or malaria in pregnancy each carry their own significant risks to mother and fetus. Decisions should always be individualised and made jointly with a treating physician. 

Driving and Alcohol 

HCQS 400mg may cause dizziness or visual disturbances — avoid driving or operating machinery until you understand how the medication affects you. Limit or avoid alcohol, as it may increase gastrointestinal and hepatic side effects. 

 Recommended Long-Term Monitoring for HCQS 400mg 

• Baseline and periodic ophthalmologic examination — annual after 5 years of continuous use for low-risk patients, sooner for high-risk patients, per the 2026 AAO revision 
• Periodic complete blood count (CBC) — white blood cells, haemoglobin, platelets 
• Blood glucose monitoring, particularly in diabetic patients or those on antidiabetic medications 
• Muscle strength and deep tendon reflex assessment for long-term users 
• Cardiac evaluation in patients with arrhythmia risk factors or those on other QT-prolonging medications 
• Renal and hepatic function monitoring periodically 

 Storage Instructions 

• Store at room temperature, in a dry, dark place away from direct sunlight and moisture 
• Keep tablets intact in their original packaging until use 
• Store out of reach of children and pets 
• Check the expiry date before use; do not take expired medication 

Frequently Asked Questions (FAQs) 

What is the generic name for HCQS 400mg? 

The generic name is Hydroxychloroquine Sulfate. HCQS is a brand name used by manufacturer IPCA Laboratories. 

What is the US brand equivalent? 

The equivalent branded product is Plaquenil, originally FDA-approved in 1955. 

Can children take HCQS 400mg? 

Not without careful medical evaluation — and this contradicts a claim in a competitor document. The FDA label specifically states hydroxychloroquine sulfate tablets are not recommended for paediatric patients weighing less than 31 kg, because the tablet cannot be safely divided to provide an appropriate lower dose. Dosing in children who do qualify is weight-based and must be determined by a paediatric specialist. 

Is HCQS 400mg safe during pregnancy? 

This is not a simple yes/no. The decision involves weighing the risks of untreated maternal disease (lupus, rheumatoid arthritis, or malaria) against any potential medication risk, and must be individualised with a treating physician — it is not accurate to describe the medication as “generally safe” without this context. 

Why does HCQS 400mg require eye exams? 

At 400mg/day, many patients — particularly those weighing less than 80kg — exceed the recommended 5mg/kg retinopathy-safe dosing ceiling. Long-term use carries a risk of irreversible retinal toxicity, and the American Academy of Ophthalmology recommends structured screening (visual fields and OCT imaging) to catch early signs before symptomatic vision loss occurs, since damage can progress even after the drug is stopped. 

Can HCQS 400mg affect my heart? 

Yes. The FDA label warns of post-marketing reports of life-threatening and fatal cardiomyopathy, and QT interval prolongation that can lead to serious ventricular arrhythmias including torsades de pointes. Report palpitations, fainting, or irregular heartbeat promptly. 

Can I take cimetidine with HCQS 400mg? 

Caution is advised. Cimetidine has been shown to double chloroquine blood levels, and a similar effect on hydroxychloroquine cannot be ruled out. This combination should generally be avoided or managed with close monitoring and dose adjustment by your doctor. 

How long does it take for HCQS 400mg to work? 

For rheumatoid arthritis and lupus, the action is cumulative and may take weeks to months to reach maximum effect. Continue treatment as prescribed even before full benefit is apparent. 

Medical Disclaimer 

All information in this guide is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. HCQS 400mg is a prescription-only medication and should only be used under the supervision of a licensed healthcare provider, with appropriate ophthalmologic and laboratory monitoring for long-term use. Never self-medicate or adjust your dose without medical guidance. In an emergency, contact local emergency services immediately. Report suspected adverse effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.